We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Glucose Levels Linked to Maternal Mortality Even in Non-Diabetic Women

By LabMedica International staff writers
Posted on 02 Jun 2020
The prevalence of diabetes mellitus (DM) and obesity have rapidly increased worldwide. More...
Serum glycated hemoglobin A1c (HbA1c), expressed as an absolute percent (e.g., 5.5%), offers a convenient and representative measure of average blood glucose control among individuals with DM.

The relation between pre-pregnancy average glucose concentration and a woman’s risk of severe maternal morbidity (SMM) is unknown. A team of scientists have evaluated whether an elevated preconception hemoglobin A1c (HbA1c) is associated with SMM or maternal death among women with and without known pre-pregnancy diabetes mellitus (DM).

A team of Canadian scientists working with those at the University of Toronto (Toronto, ON, Canada) analyzed data in a study of 31,225 women aged 16 through 50 years with a hospital live birth or stillbirth and who had an HbA1c measured within 90 days before conception. 28,075 of the women (90%) did not have a known diagnosis of diabetes mellitus.

The investigators reported that overall, the risk of severe maternal morbidity (SMM) or death from 23 weeks gestation to 6 weeks postpartum was 2.2%. For each 0.5% absolute increase in HbA1c, the relative risk of SMM or death was 1.16 after adjusting for maternal age, multifetal pregnancy, world region of origin, and tobacco/drug dependence. Compared to those with a healthy preconception HbA1c of below 5.8%, the adjusted relative risk of SMM or death was 1.31 in those with a preconception HbA1c of 5.8-6.4% and 2.84 in those with a preconception HbA1c greater than 6.4%. Among women without a diagnosis of diabetes who had an HbA1c over 6.4%, the adjusted relative risk was 3.25.

The authors concluded that women with an elevated HbA1c, preconception or in early pregnancy, had an increased risk of SMM or death. Given its convenience and widespread use, HbA1c testing may also identify those women with preexisting DM at risk of SMM, in a manner similar to its current use in recognizing those at higher risk of fetal anomalies, preterm birth, and preeclampsia. As there is no current recommendation about HbA1c testing in non-diabetic pregnant women, especially those with obesity and/or chronic hypertension, these findings may enhance the knowledge about the benefits of A1c screening in these women. The study was published on May 19, 2020 in the journal PLOS Medicine.

Related Links:
University of Toronto


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.